49705-66-0

Basic information

• Product Name: 2-(4-CHLORO-2-BUTENYL)-1,3-ISOINDOLINEDIONE
• Synonyms: 2-(4-CHLORO-2-BUTENYL)-1,3-ISOINDOLINEDIONE;TRANS-N-(4-CHLOROBUTENYL) PHTHALIMIDE
• CAS NO: 49705-66-0
• Molecular Formula: C₁₂H₁₀ClNO₂
• Molecular Weight: 235.67
• Mol File: 49705-66-0.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-CHLORO-2-BUTENYL)-1,3-ISOINDOLINEDIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-CHLORO-2-BUTENYL)-1,3-ISOINDOLINEDIONE(49705-66-0)
• EPA Substance Registry System: 2-(4-CHLORO-2-BUTENYL)-1,3-ISOINDOLINEDIONE(49705-66-0)

Safety Data

• Hazardous Substances Data: 49705-66-0(Hazardous Substances Data)

Usage

Chemical Family

2-(4-chloro-2-butenyl)-1,3-isoindolinedione belongs to the family of isoindolinediones.

Physical Form

It is a crystalline solid.

Color

It has a pale yellow color.

Solubility

It is soluble in organic solvents.

Uses

It is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals.

Medicinal Properties

It has been studied for its potential anti-inflammatory and analgesic properties, making it an important target for medicinal chemistry research.

Toxicity

It is known to be toxic and may cause irritation upon contact with skin or eyes.

Upstream product

• 1074-82-4 2,3-dihydro-1H-isoindole-1,3-dione potassium 
• 110-57-6 trans-1,4-dichlorobut-2-ene 
• 1074-82-4 potassium phtalimide 
• 764-41-0 1,4-dichloro-2-butene 
• 136918-14-4 phthalimide 

Downstream Products

• 121030-30-6 3-Butyl-3-hydroxy-2-((2E,4E)-5-phenyl-penta-2,4-dienyl)-2,3-dihydro-isoindol-1-one 
• 77629-06-2 (2Z,4E)-5-phenyl-1-(N-phthalimido)-2,4-pentadiene 
• 77629-05-1 2-((2E,4E)-5-phenylpenta-2,4-dien-1-yl)isoindoline-1,3-dione 
• 121030-17-9 (2Z)-4-cyclohexylidene-1-(N-phthalimido)-2-butene 
• 121030-10-2 (2E)-4-cyclohexylidene-1-(N-phthalimido)-2-butene 
• 121030-13-5 (2Z,4E,6E)-7-phenyl-1-(N-phthalimido)-2,4,6-heptatriene 
• 121030-06-6 (2,E,4E,6E)-7-phenyl-1-(N-phthalimido)-2,4,6-heptatriene 
• 121055-36-5 (2Z,4E)-5-(4'-chlorophenyl)-1-(N-phthalimido)-2,4-pentadiene 
• 121030-04-4 (2E,4E)-5-(4'-chlorophenyl)-1-(N-phthalimido)-2,4-pentadiene 
• 121030-11-3 (2Z,4E)-5-(4'-methoxyphenyl)-1-(N-phthalimido)-2,4-pentadiene 
• 121030-03-3 (2E,4E)-5-(4'-methoxyphenyl)-1-(N-phthalimido)-2,4-pentadiene 
• 1875-48-5 N-aminophthalamide 
• 675599-75-4 2-[(E)-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-enyl]isoindoline-1,3-dione 

Relevant articles and documents

A reinvestigation of the synthesis and properties of trans-4,5-dehydrolysine.

-

Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase

We recently reported molecules designed according to the multitarget-directed ligand paradigm to exert combined activity at human fatty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 (D3R). Both targets are relevant for tackling several types of addiction (most notably nicotine addiction) and other compulsive behaviors. Here, we report an SAR exploration of a series of biphenyl-N-[4-[4-(2,3-substituted-phenyl)piperazine-1-yl]alkyl]carbamates, a novel class of molecules that had shown promising activities at the FAAH-D3R target combination in preliminary studies. We have rationalized the structural features conducive to activities at the main targets and investigated activities at two off-targets: dopamine receptor subtype D2 and endocannabinoid receptor CB1. To understand the unexpected affinity for the CB1 receptor, we devised a 3D-QSAR model, which we then prospectively validated. Compound 33 was selected for PK studies because it displayed balanced affinities for the main targets and clear selectivity over the two off-targets. 33 has good stability and oral bioavailability and can cross the blood-brain barrier.

NOVEL DOPAMINE D3 RECEPTOR LIGANDS AND PREPARATION AND MEDICAL USES OF THE SAME

The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson''s disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.